化疗所致周围神经病变的临床研究现状
|
摘要
化疗所致周围神经病变(chemotherapy-induced peripheral neuropathy,CIPN)是限制抗肿瘤药物使用的常见毒副反应之一,在治疗消化道肿瘤的化疗药物中尤为常见,以铂类及紫杉类为主。由于CIPN具体的发病机制尚未明确,目前仍未有确切有效的防治策略及药物,度洛西汀是目前唯一推荐使用治疗CIPN相关疼痛的药物。针灸与中药显示出较好的疗效。本文主要就CIPN的中西医研究现状进行综述,以期为研发新的防治策略提供依据。
Chemotherapy induced peripheral neuropathy( CIPN) is one of the common side effects of restricting the use of antineoplastic drugs. It is especially common in chemotherapeutics for gastrointestinal tumors,and it is mainly occur when use platinum and taxus. Because the specific pathogenesis of CIPN is not yet clear,there are no effective preventive strategies and drugs. Duloxetine is the only drug recommended for treating CIPN related pain currently. Acupuncture and Chinese medicine have shown good curative effect. This article mainly reviews the current research status of CIPN in the Western medicine and Chinese medicine in order to provide a basis for developing new prevention strategies.
Chemotherapy induced peripheral neuropathy( CIPN) is one of the common side effects of restricting the use of antineoplastic drugs. It is especially common in chemotherapeutics for gastrointestinal tumors,and it is mainly occur when use platinum and taxus. Because the specific pathogenesis of CIPN is not yet clear,there are no effective preventive strategies and drugs. Duloxetine is the only drug recommended for treating CIPN related pain currently. Acupuncture and Chinese medicine have shown good curative effect. This article mainly reviews the current research status of CIPN in the Western medicine and Chinese medicine in order to provide a basis for developing new prevention strategies.
引文
[1] Staff NP,Grisold A,Grisold W,et al. Chemotherapy-induced peripheral neuropathy:A current review[J]. Annals of Neurology,2017,81(6):772.
[2] Ma J,Kavelaars A,Dougherty PM,et al. Beyond symptomatic relief for chemotherapy-induced peripheral neuropathy:Targeting the source[J]. Cancer,2018,124(11):2289-2298.
[3] Kerckhove N,Collin A,CondéS,et al. Long-term effects,pathophysiological mechanisms,and risk factors of chemotherapy-induced peripheral neuropathies:A comprehensive literature review[J]. Front Pharmacol,2017,8:86.
[4] Flatters SJL,Dougherty PM,Colvin LA. Clinical and preclinical perspectives on chemotherapy-induced peripheral neuropathy(CIPN):A narrative review[J]. Br J Anaesth,2017,119(4):737-749.
[5] Bakogeorgos M,Georgoulias V. Risk-reduction and treatment of chemotherapy-induced peripheral neuropathy[J]. Expert Review of Anticancer Therapy,2017,17(11):1045-1060.
[6] Hershman DL,Lacchetti C,Dworkin RH,et al. American society of clinical oncology prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers:American society of clinical oncology clinical practice guideline[J]. J Clin Oncol,2014,32:1941-1967.
[7] Majithia N,Temkin SM,Ruddy KJ,et al. National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials:Outcomes and lessons[J]. Support Care Cancer,2016,24(3):1439-1447.
[8] Carvalho LF,Silva AMF,Carvalho AA. The use of antioxidant agents for chemotherapy-induced peripheral neuropathy treatment in animal models[J]. Clin Exp Pharmacol Physiol,2017,4(10):971-979.
[9] Saad M,Tafani C,Psimaras D,et al. Chemotherapy-induced peripheral neuropathy in the adult[J]. Curr Opin Oncol,2014,26(6):634-641.
[10] Avan A,Postma TJ,Ceresa C,et al. Platinum-induced neurotoxicity and preventive strategies:Past,present,and future[J]. Oncologist,2015,20(4):411.
[11] Argyriou AA,Bruna J,Marmiroli P,et al. Chemotherapy-induced peripheral neurotoxicity(CIPN):An update[J]. Crit Rev Oncol Hematol,2012,82:51-77.
[12] Argyriou AA,Cavaletti G,Antonacopoulou A,et al. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity:Results from a prospective multicenter study[J]. Cancer,2013,119:3570-3577.
[13] Palugulla S,Dkhar SA,Kayal S,et al. Oxaliplatin-induced peripheral neuropathy in south indian cancer patients:A prospective study in digestive tract cancer patients[J]. Indian Journal of Medical&Paediatric Oncology:Official Journal of Indian Society of Medical&Paediatric Oncology,2017,38(4):502.
[14] Shahriari-Ahmadi A,Fahimi A,Payandeh M,et al. Prevalence of oxaliplatin-induced chronic neuropathy and influencing factors in patients with colorectal cancer in Iran[J]. Asian Pac J Cancer Prev,2015,16:7603-7606.
[15] Raphael MJ,Fischer HD,Fung K,et al. Neurotoxicity outcomes in a population-based cohort of elderly patients treated with adjuvant oxaliplatin for colorectal cancer[J]. Clinical Colorectal Cancer,2017,16(4):397-404.
[16] Argyriou AA,Velasco R,Briani C,et al. Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil(FOLFOX)or capecitabine(XELOX):A prospective evaluation of 150 colorectal cancer patients[J]. Annals of Oncology,2012,23(12):3116-3122.
[17] Vincenzi B,Frezza AM,Schiavon G,et al. Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant FOLFOXⅣ[J]. Support Care Cancer,2012,30:125-128.
[18] Alejandro LM,Behrendt CE,Chen K,et al. Predicting acute and persistent neuropathy associated with oxaliplatin[J]. Am J Clin Oncol,2012,27:63-72.
[19] Song SJ,Min J,Suh SY,et al. Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer[J]. Supportive Care in Cancer:Official Journal of the Multinational Association of Supportive Care in Cancer,2017,25(7):2241-2248.
[20] Loprinzi CL,Reeves BN,Dakhil SR,et al. Natural history of paclitaxel-associated acute pain syndrome:Prospective cohort study NCCTG N08C1[J]. J Clin Oncol,2011,29:1472-1478.
[21] Reeves BN,Dakhil SR,Sloan JA,et al. Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy:North Central Cancer Treatment Group trial N08C1[J]. Cancer,2012,118(20):5171-5178.
[22] Chaudhry V,Rowinsky EK,Sartorius SE,et al. Peripheral neuropathy from taxol and cisplatin combination chemotherapy:Clinical and electrophysiological studies[J]. Annals of Neurology,1994,35(3):304-311.
[23] Pignata S,Scambia G,Katsaros D,et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer(MITO-7):A randomised,multicentre,open-label,phase 3 trial[J]. Lancet Oncology,2014,15(4):396-405.
[24] Katsumata N,Yasuda M,Takahashi F,et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer:A phase 3,open-label,randomised controlled trial[J]. Lancet,2009,374(9698):1331-1338.
[25] Argyriou AA,Polychronopoulos P,Iconomou G,et al. Paclitaxel plus carboplatin-induced peripheral neuropathy. A prospective clinical and electrophysiological study in patients suffering from solid malignancies[J]. Digest of the World Core Medical Journals,2005,252(12):1459-1464.
[26] Sandro P,Sabino DP,Rosalbino B,et al. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel:The multicenter Italian trial in ovarian cancer(MITO-4)retrospective study[J]. Bmc Cancer,2006,6(1):1-7.
[27] De la Morena Barrio P,Conesa MA,González-Billalabeitia E,et al. Delayed recovery and increased severity of Paclitaxel-induced peripheral neuropathy in patients with diabetes[J]. Journal of the National Comprehensive Cancer Network,2015,13(4):417-423.
[28] Toki MI,Saif MW,Syrigos KN. Hypersensitivity reactions associated with oxaliplatin and their clinical management[J]. Expert Opinion on Drug Safety,2014,13(11):1545-1554.
[29] Zhang X,Zhao Y,Zheng Y,et al. The effects of prolonged infusion on reducing oxaliplatin hypersensitivity reactions[J]. J Investig Allergol Clin Immunol,2017,27(1):65-66.
[30] Grothey A. Clinical management of oxaliplatin-associated neurotoxicity[J]. Clin Colorectal Cancer,2005,5(Suppl 1):S38-S46.
[31] Grothey A,Nikcevich DA,Sloan JA,et al. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer:NCCTG N04C7[J]. J Clin Oncol,2011,29(4):421-427.
[32] Loprinzi CL,Qin R,Dakhil SR,et al. PhaseⅢrandomized,placebo-controlled,double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity(N08CB/Alliance)[J]. J Clin Oncol,2014,32:997-1005.
[33] Huang JS,Wu CL,Fan CW,et al. Intravenous glutamine appears to reduce the severity of symptomatic platinum-induced neuropathy:A prospective randomized study[J]. Journal of Chemotherapy,2015,27(4):235-240.
[34] Shinde SS,Seisler D,Soori G,et al. Can pregabalin prevent paclitaxel-associated neuropathy? An ACCRU pilot trial[J]. Supportive Care in Cancer,2016,24(2):547-553.
[35] De Andrade DC,Jacobsen TM,Galhardoni R,et al. Pregabalin for the prevention of oxaliplatin-Induced painful neuropathy:A randomized,double-blind trial[J]. Oncologist,2017,22(10):1154.
[36] Youk J,Kim YS,Lim JA,et al. Depletion of nerve growth factor in chemotherapy-induced peripheral neuropathy associated with hematologic malignancies[J]. PLo S One,2017,12(8):e0183491.
[37] Velasco R,Navarro X,Gilgil M,et al. Neuropathic pain and nerve growth factor in chemotherapy-induced peripheral neuropathy:Prospective clinical-pathological study[J]. Journal of Pain&Symptom Management,2017,54(6):815-825.
[38] Chen XF,Wang R,Yin YM,et al. The effect of monosialotetrahexosylganglioside(GM1)in prevention of oxaliplatin induced neurotoxicity:A retrospective study[J]. Biomedicine&Pharmacotherapy,2012,66(4):279-284.
[39] Zhu Y,Yang J,Jiao S,et al. Ganglioside-monosialic acid(GM1)prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors[J]. World Journal of Surgical Oncology,2013,11(1):19.
[40] Kelly GS. L-carnitine:Therapeutic applications of a conditionally-essential amino acid[J]. Altern Med Rev,1998,3:345-360.
[41] Bianchi G,Vitali G,Caraceni A,et al. Symptomatic and neurophysiological responses of paclitaxel-or cisplatin-induced neuropathy to oral acetyl-L-carnitine[J]. Eur J Cancer,2005,41:1746-1750.
[42] Hershman DL,Unger JM,Crew KD,et al. Two-year trends of taxane-induced neuropathy in women enrolled in a randomized trial of acetyl-l-carnitine(SWOG S0715)[J]. J Natl Cancer Inst,2018,110(6):669-676.
[43] Li SD,Shi JH,Li XJ. Preventive effect of mecobalamin combined with glutathione on neurotoxicity induced by FOLFOX4 chemotherapy[J]. Chinese Journal of Oncology,2016,38(8):632-635.
[44] Han X,Wang L,Shi H,et al. Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma[J]. Bmc Cancer,2017,17(1):40.
[45] Smith EM,Pang H,Cirrincione C,et al. Effect of duloxetine on pain,function,and quality of life among patients with chemotherapy-induced painful peripheral neuropathy:A randomized clinical trial[J]. JAMA,2013,309(13):1359-1367.
[46] Takenaka M,Iida H,Matsumoto S,et al. Successful treatment by adding duloxetine to pregabalin for peripheral neuropathy induced by paclitaxel[J]. Am J Hosp Palliat Care,2013,30:734-736.
[47] Taillibert S,Le Rhun E,Chamberlain MC. Chemotherapy-related neurotoxicity[J]. Curr Neurol Neurosci Rep,2016,16(9):81.
[48] Hirayama Y,Ishitani K,Sato Y,et al. Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy:A pilot randomized trial[J]. International Journal of Clinical Oncology,2015,20(5):866-871.
[49] Kanbayashi Y,Inagaki M,Ueno H,et al. Predictors of the usefulness of duloxetine for chemotherapy-induced peripheral neuropathy[J]. Medical Oncology,2017,34(8):137.
[50] Kus T,Aktas G,Alpak G,et al. Efficacy of venlafaxine for the relief of taxane and oxaliplatin-induced acute neurotoxicity:A single-center retrospective case-control study[J]. Supportive Care in Cancer,2016,24(5):2085-2091.
[51] Zimmerman C,Atherton PJ,Pachman D,et al. MC11C4:A pilot randomized,placebo-controlled,double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy[J]. Supportive Care in Cancer,2016,24(3):1-8.
[52] Aziz MT,Good BL,Lowe DK. Serotonin-norepinephrine reuptake inhibitors for the management of chemotherapy-induced peripheral neuropathy[J]. Annals of Pharmacotherapy,2014,48(5):626.
[53] Rao RD,Michalak JC,Sloan JA,et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy:A phase 3 randomized,double-blind,placebo-controlled,crossover trial(N00C3)[J]. Cancer,2007,110:2110-2118.
[54] Bove L,Picardo M,Maresca V,et al. A pilot study on the relation between cisplatin neuropathy and vitamin E[J]. J Exp Clin Cancer Res,2001,20:277-280.
[55] Argyriou AA,Chroni E,Koutras A,et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy:A randomized controlled trial[J]. Neurology,2005,64:26-31.
[56] Huang H,Mei H,Liu L,et al. Vitamin E does not decrease the incidence of chemotherapy-induced peripheral neuropathy:A Meta-analysis[J]. Contemporary Oncology,2016,20(3):237-241.
[57] Kottschade LA,Sloan JA,Mazurczak MA,et al. The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy:Results of a randomized phaseⅢclinical trial[J]. Supportive Care in Cancer:Official Journal of the Multinational Association of Supportive Care in Cancer,2011,19(11):1769.
[58] Guichet X,Jouniaux L,Catel N. Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy[J]. Annals of Pharmacotherapy,2008,42(10):1481-1485.
[59] Ibrahimpasic K. Alpha lipoic acid and glycaemic control in diabetic neuropathies at type 2 diabetes treatment[J]. Med Arch,2013,67:7-9.
[60] Guo Y,Jones D,Palmer JL,et al. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy:A randomized,double-blind,placebo-controlled trial[J]. Support Care Cancer,2014,22:1223-1231.
[61] Glimelius B,Manojlovic N,Pfeiffer P,et al. Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir Pled Ox:A placebo-controlled randomised phaseⅡstudy(PLIANT)[J]. Acta Oncologica,2018,57(3):393-402.
[62] Ben-Horin I,Kahan P,Ryvo L,et al.Acupuncture and reflexology for chemotherapy-induced peripheral neuropathy in breast cancer[J].Integrative Cancer Therapies,2017,16(3):258-262.
[63] Majithia N,Smith TJ,Coyne PJ,et al. Scrambler Therapy for the management of chronic pain[J]. Supportive Care in Cancer,2016,24(6):2807-2814.
[64] Greenlee H,Crew KD,Capodice J,et al. Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer[J]. Breast Cancer Research&Treatment,2016,156(3):453-464.
[65] Shi Yue,Li Chonghui. Progress in treatment of chemotherapeutic agents induced peripheral neurotoxicity with integrated traditional Chinese and Western Medicine[J]. Clinical Journal of Traditional Chinese Medicine,2017,29(03):327-330.[师悦,李崇慧.化疗药所致周围神经毒性中西医治疗进展[J].中医药临床杂志,2017,29(03):327-330.]
[66] Huang Zhongyu,Yang Qiong,Mei Mingzhu,et al. Research progress in prevention and treatment of peripheral neurotoxicity of oxaliplatin by Chinese medicine[J]. Hebei J TCM,2016,38(12):1895-1898.[黄忠瑜,杨琼,梅命珠,等.中医防治奥沙利铂周围神经毒性的研究进展[J].河北中医,2016,38(12):1895-1898.]
[67] Deng B,Jia L,Cheng Z. Radix astragali-based Chinese herbal medicine for oxaliplatin-induced peripheral neuropathy:A systematic review and Meta-analysis[J]. Evidence-Based Complementray and Alternative Medicine,2016,2016(4):1-14.
[68] Cao Peng,Li Songlin,Huo Jiege. Treatment of oxaliplatin related peripheral neuropathy with blood stagnation[J]. Chinese Journal of Basic Medicine of Traditional Chinese Medicine,2013,19(04):430-431.[曹鹏,李松林,霍介格.奥沙利铂相关性周围神经病变以血痹论治析[J].中国中医基础医学杂志,2013,19(04):430-431.]
[69] Huo Jiege,Hu Yin,Yang Jie,et al. Effect of Huangqi Guizhi Wuwu Decoction on chemotherapy-induced peripheral never injury in rats[J]. Journal of Traditional Chinese Medicine,2012,53(23):2031-2034.[霍介格,胡莹,杨杰,等.黄芪桂枝五物汤对化疗致大鼠周围神经损伤的作用[J].中医杂志,2012,53(23):2031-2034.]
[70] Cheng XL,Huo JG,Wang DW,et al. Herbal medicine AC591 prevents oxaliplatin-induced peripheral neuropathy in animal model and cancer patients[J]. Frontiers in Pharmacology,2017,8:344.
[71] Curcio KR. Instruments for assessing chemotherapy-induced peripheral neuropathy:A review of the literature[J]. Clinical Journal of Oncology Nursing,2016,20(2):144-151.
[2] Ma J,Kavelaars A,Dougherty PM,et al. Beyond symptomatic relief for chemotherapy-induced peripheral neuropathy:Targeting the source[J]. Cancer,2018,124(11):2289-2298.
[3] Kerckhove N,Collin A,CondéS,et al. Long-term effects,pathophysiological mechanisms,and risk factors of chemotherapy-induced peripheral neuropathies:A comprehensive literature review[J]. Front Pharmacol,2017,8:86.
[4] Flatters SJL,Dougherty PM,Colvin LA. Clinical and preclinical perspectives on chemotherapy-induced peripheral neuropathy(CIPN):A narrative review[J]. Br J Anaesth,2017,119(4):737-749.
[5] Bakogeorgos M,Georgoulias V. Risk-reduction and treatment of chemotherapy-induced peripheral neuropathy[J]. Expert Review of Anticancer Therapy,2017,17(11):1045-1060.
[6] Hershman DL,Lacchetti C,Dworkin RH,et al. American society of clinical oncology prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers:American society of clinical oncology clinical practice guideline[J]. J Clin Oncol,2014,32:1941-1967.
[7] Majithia N,Temkin SM,Ruddy KJ,et al. National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials:Outcomes and lessons[J]. Support Care Cancer,2016,24(3):1439-1447.
[8] Carvalho LF,Silva AMF,Carvalho AA. The use of antioxidant agents for chemotherapy-induced peripheral neuropathy treatment in animal models[J]. Clin Exp Pharmacol Physiol,2017,4(10):971-979.
[9] Saad M,Tafani C,Psimaras D,et al. Chemotherapy-induced peripheral neuropathy in the adult[J]. Curr Opin Oncol,2014,26(6):634-641.
[10] Avan A,Postma TJ,Ceresa C,et al. Platinum-induced neurotoxicity and preventive strategies:Past,present,and future[J]. Oncologist,2015,20(4):411.
[11] Argyriou AA,Bruna J,Marmiroli P,et al. Chemotherapy-induced peripheral neurotoxicity(CIPN):An update[J]. Crit Rev Oncol Hematol,2012,82:51-77.
[12] Argyriou AA,Cavaletti G,Antonacopoulou A,et al. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity:Results from a prospective multicenter study[J]. Cancer,2013,119:3570-3577.
[13] Palugulla S,Dkhar SA,Kayal S,et al. Oxaliplatin-induced peripheral neuropathy in south indian cancer patients:A prospective study in digestive tract cancer patients[J]. Indian Journal of Medical&Paediatric Oncology:Official Journal of Indian Society of Medical&Paediatric Oncology,2017,38(4):502.
[14] Shahriari-Ahmadi A,Fahimi A,Payandeh M,et al. Prevalence of oxaliplatin-induced chronic neuropathy and influencing factors in patients with colorectal cancer in Iran[J]. Asian Pac J Cancer Prev,2015,16:7603-7606.
[15] Raphael MJ,Fischer HD,Fung K,et al. Neurotoxicity outcomes in a population-based cohort of elderly patients treated with adjuvant oxaliplatin for colorectal cancer[J]. Clinical Colorectal Cancer,2017,16(4):397-404.
[16] Argyriou AA,Velasco R,Briani C,et al. Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil(FOLFOX)or capecitabine(XELOX):A prospective evaluation of 150 colorectal cancer patients[J]. Annals of Oncology,2012,23(12):3116-3122.
[17] Vincenzi B,Frezza AM,Schiavon G,et al. Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant FOLFOXⅣ[J]. Support Care Cancer,2012,30:125-128.
[18] Alejandro LM,Behrendt CE,Chen K,et al. Predicting acute and persistent neuropathy associated with oxaliplatin[J]. Am J Clin Oncol,2012,27:63-72.
[19] Song SJ,Min J,Suh SY,et al. Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer[J]. Supportive Care in Cancer:Official Journal of the Multinational Association of Supportive Care in Cancer,2017,25(7):2241-2248.
[20] Loprinzi CL,Reeves BN,Dakhil SR,et al. Natural history of paclitaxel-associated acute pain syndrome:Prospective cohort study NCCTG N08C1[J]. J Clin Oncol,2011,29:1472-1478.
[21] Reeves BN,Dakhil SR,Sloan JA,et al. Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy:North Central Cancer Treatment Group trial N08C1[J]. Cancer,2012,118(20):5171-5178.
[22] Chaudhry V,Rowinsky EK,Sartorius SE,et al. Peripheral neuropathy from taxol and cisplatin combination chemotherapy:Clinical and electrophysiological studies[J]. Annals of Neurology,1994,35(3):304-311.
[23] Pignata S,Scambia G,Katsaros D,et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer(MITO-7):A randomised,multicentre,open-label,phase 3 trial[J]. Lancet Oncology,2014,15(4):396-405.
[24] Katsumata N,Yasuda M,Takahashi F,et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer:A phase 3,open-label,randomised controlled trial[J]. Lancet,2009,374(9698):1331-1338.
[25] Argyriou AA,Polychronopoulos P,Iconomou G,et al. Paclitaxel plus carboplatin-induced peripheral neuropathy. A prospective clinical and electrophysiological study in patients suffering from solid malignancies[J]. Digest of the World Core Medical Journals,2005,252(12):1459-1464.
[26] Sandro P,Sabino DP,Rosalbino B,et al. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel:The multicenter Italian trial in ovarian cancer(MITO-4)retrospective study[J]. Bmc Cancer,2006,6(1):1-7.
[27] De la Morena Barrio P,Conesa MA,González-Billalabeitia E,et al. Delayed recovery and increased severity of Paclitaxel-induced peripheral neuropathy in patients with diabetes[J]. Journal of the National Comprehensive Cancer Network,2015,13(4):417-423.
[28] Toki MI,Saif MW,Syrigos KN. Hypersensitivity reactions associated with oxaliplatin and their clinical management[J]. Expert Opinion on Drug Safety,2014,13(11):1545-1554.
[29] Zhang X,Zhao Y,Zheng Y,et al. The effects of prolonged infusion on reducing oxaliplatin hypersensitivity reactions[J]. J Investig Allergol Clin Immunol,2017,27(1):65-66.
[30] Grothey A. Clinical management of oxaliplatin-associated neurotoxicity[J]. Clin Colorectal Cancer,2005,5(Suppl 1):S38-S46.
[31] Grothey A,Nikcevich DA,Sloan JA,et al. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer:NCCTG N04C7[J]. J Clin Oncol,2011,29(4):421-427.
[32] Loprinzi CL,Qin R,Dakhil SR,et al. PhaseⅢrandomized,placebo-controlled,double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity(N08CB/Alliance)[J]. J Clin Oncol,2014,32:997-1005.
[33] Huang JS,Wu CL,Fan CW,et al. Intravenous glutamine appears to reduce the severity of symptomatic platinum-induced neuropathy:A prospective randomized study[J]. Journal of Chemotherapy,2015,27(4):235-240.
[34] Shinde SS,Seisler D,Soori G,et al. Can pregabalin prevent paclitaxel-associated neuropathy? An ACCRU pilot trial[J]. Supportive Care in Cancer,2016,24(2):547-553.
[35] De Andrade DC,Jacobsen TM,Galhardoni R,et al. Pregabalin for the prevention of oxaliplatin-Induced painful neuropathy:A randomized,double-blind trial[J]. Oncologist,2017,22(10):1154.
[36] Youk J,Kim YS,Lim JA,et al. Depletion of nerve growth factor in chemotherapy-induced peripheral neuropathy associated with hematologic malignancies[J]. PLo S One,2017,12(8):e0183491.
[37] Velasco R,Navarro X,Gilgil M,et al. Neuropathic pain and nerve growth factor in chemotherapy-induced peripheral neuropathy:Prospective clinical-pathological study[J]. Journal of Pain&Symptom Management,2017,54(6):815-825.
[38] Chen XF,Wang R,Yin YM,et al. The effect of monosialotetrahexosylganglioside(GM1)in prevention of oxaliplatin induced neurotoxicity:A retrospective study[J]. Biomedicine&Pharmacotherapy,2012,66(4):279-284.
[39] Zhu Y,Yang J,Jiao S,et al. Ganglioside-monosialic acid(GM1)prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors[J]. World Journal of Surgical Oncology,2013,11(1):19.
[40] Kelly GS. L-carnitine:Therapeutic applications of a conditionally-essential amino acid[J]. Altern Med Rev,1998,3:345-360.
[41] Bianchi G,Vitali G,Caraceni A,et al. Symptomatic and neurophysiological responses of paclitaxel-or cisplatin-induced neuropathy to oral acetyl-L-carnitine[J]. Eur J Cancer,2005,41:1746-1750.
[42] Hershman DL,Unger JM,Crew KD,et al. Two-year trends of taxane-induced neuropathy in women enrolled in a randomized trial of acetyl-l-carnitine(SWOG S0715)[J]. J Natl Cancer Inst,2018,110(6):669-676.
[43] Li SD,Shi JH,Li XJ. Preventive effect of mecobalamin combined with glutathione on neurotoxicity induced by FOLFOX4 chemotherapy[J]. Chinese Journal of Oncology,2016,38(8):632-635.
[44] Han X,Wang L,Shi H,et al. Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma[J]. Bmc Cancer,2017,17(1):40.
[45] Smith EM,Pang H,Cirrincione C,et al. Effect of duloxetine on pain,function,and quality of life among patients with chemotherapy-induced painful peripheral neuropathy:A randomized clinical trial[J]. JAMA,2013,309(13):1359-1367.
[46] Takenaka M,Iida H,Matsumoto S,et al. Successful treatment by adding duloxetine to pregabalin for peripheral neuropathy induced by paclitaxel[J]. Am J Hosp Palliat Care,2013,30:734-736.
[47] Taillibert S,Le Rhun E,Chamberlain MC. Chemotherapy-related neurotoxicity[J]. Curr Neurol Neurosci Rep,2016,16(9):81.
[48] Hirayama Y,Ishitani K,Sato Y,et al. Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy:A pilot randomized trial[J]. International Journal of Clinical Oncology,2015,20(5):866-871.
[49] Kanbayashi Y,Inagaki M,Ueno H,et al. Predictors of the usefulness of duloxetine for chemotherapy-induced peripheral neuropathy[J]. Medical Oncology,2017,34(8):137.
[50] Kus T,Aktas G,Alpak G,et al. Efficacy of venlafaxine for the relief of taxane and oxaliplatin-induced acute neurotoxicity:A single-center retrospective case-control study[J]. Supportive Care in Cancer,2016,24(5):2085-2091.
[51] Zimmerman C,Atherton PJ,Pachman D,et al. MC11C4:A pilot randomized,placebo-controlled,double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy[J]. Supportive Care in Cancer,2016,24(3):1-8.
[52] Aziz MT,Good BL,Lowe DK. Serotonin-norepinephrine reuptake inhibitors for the management of chemotherapy-induced peripheral neuropathy[J]. Annals of Pharmacotherapy,2014,48(5):626.
[53] Rao RD,Michalak JC,Sloan JA,et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy:A phase 3 randomized,double-blind,placebo-controlled,crossover trial(N00C3)[J]. Cancer,2007,110:2110-2118.
[54] Bove L,Picardo M,Maresca V,et al. A pilot study on the relation between cisplatin neuropathy and vitamin E[J]. J Exp Clin Cancer Res,2001,20:277-280.
[55] Argyriou AA,Chroni E,Koutras A,et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy:A randomized controlled trial[J]. Neurology,2005,64:26-31.
[56] Huang H,Mei H,Liu L,et al. Vitamin E does not decrease the incidence of chemotherapy-induced peripheral neuropathy:A Meta-analysis[J]. Contemporary Oncology,2016,20(3):237-241.
[57] Kottschade LA,Sloan JA,Mazurczak MA,et al. The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy:Results of a randomized phaseⅢclinical trial[J]. Supportive Care in Cancer:Official Journal of the Multinational Association of Supportive Care in Cancer,2011,19(11):1769.
[58] Guichet X,Jouniaux L,Catel N. Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy[J]. Annals of Pharmacotherapy,2008,42(10):1481-1485.
[59] Ibrahimpasic K. Alpha lipoic acid and glycaemic control in diabetic neuropathies at type 2 diabetes treatment[J]. Med Arch,2013,67:7-9.
[60] Guo Y,Jones D,Palmer JL,et al. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy:A randomized,double-blind,placebo-controlled trial[J]. Support Care Cancer,2014,22:1223-1231.
[61] Glimelius B,Manojlovic N,Pfeiffer P,et al. Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir Pled Ox:A placebo-controlled randomised phaseⅡstudy(PLIANT)[J]. Acta Oncologica,2018,57(3):393-402.
[62] Ben-Horin I,Kahan P,Ryvo L,et al.Acupuncture and reflexology for chemotherapy-induced peripheral neuropathy in breast cancer[J].Integrative Cancer Therapies,2017,16(3):258-262.
[63] Majithia N,Smith TJ,Coyne PJ,et al. Scrambler Therapy for the management of chronic pain[J]. Supportive Care in Cancer,2016,24(6):2807-2814.
[64] Greenlee H,Crew KD,Capodice J,et al. Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer[J]. Breast Cancer Research&Treatment,2016,156(3):453-464.
[65] Shi Yue,Li Chonghui. Progress in treatment of chemotherapeutic agents induced peripheral neurotoxicity with integrated traditional Chinese and Western Medicine[J]. Clinical Journal of Traditional Chinese Medicine,2017,29(03):327-330.[师悦,李崇慧.化疗药所致周围神经毒性中西医治疗进展[J].中医药临床杂志,2017,29(03):327-330.]
[66] Huang Zhongyu,Yang Qiong,Mei Mingzhu,et al. Research progress in prevention and treatment of peripheral neurotoxicity of oxaliplatin by Chinese medicine[J]. Hebei J TCM,2016,38(12):1895-1898.[黄忠瑜,杨琼,梅命珠,等.中医防治奥沙利铂周围神经毒性的研究进展[J].河北中医,2016,38(12):1895-1898.]
[67] Deng B,Jia L,Cheng Z. Radix astragali-based Chinese herbal medicine for oxaliplatin-induced peripheral neuropathy:A systematic review and Meta-analysis[J]. Evidence-Based Complementray and Alternative Medicine,2016,2016(4):1-14.
[68] Cao Peng,Li Songlin,Huo Jiege. Treatment of oxaliplatin related peripheral neuropathy with blood stagnation[J]. Chinese Journal of Basic Medicine of Traditional Chinese Medicine,2013,19(04):430-431.[曹鹏,李松林,霍介格.奥沙利铂相关性周围神经病变以血痹论治析[J].中国中医基础医学杂志,2013,19(04):430-431.]
[69] Huo Jiege,Hu Yin,Yang Jie,et al. Effect of Huangqi Guizhi Wuwu Decoction on chemotherapy-induced peripheral never injury in rats[J]. Journal of Traditional Chinese Medicine,2012,53(23):2031-2034.[霍介格,胡莹,杨杰,等.黄芪桂枝五物汤对化疗致大鼠周围神经损伤的作用[J].中医杂志,2012,53(23):2031-2034.]
[70] Cheng XL,Huo JG,Wang DW,et al. Herbal medicine AC591 prevents oxaliplatin-induced peripheral neuropathy in animal model and cancer patients[J]. Frontiers in Pharmacology,2017,8:344.
[71] Curcio KR. Instruments for assessing chemotherapy-induced peripheral neuropathy:A review of the literature[J]. Clinical Journal of Oncology Nursing,2016,20(2):144-151.